Emcure Pharmaceuticals Limited — Investor Meet, 28-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Emcure has announced a board meeting to consider the financial results for the quarter and half-year. Q4 FY25 revenue rose 19.5% YoY to INR 2,116 Cr, led by 25% domestic and 16% international growth. EBITDA margin improved to 18.4%, and PAT surged 63% YoY to INR 197 Cr. FY25 revenue grew 19% to INR 7,896 Cr with PAT at INR 707 Cr, up 34%. Net debt reduced sharply to INR 488 Cr. Strong domestic growth was driven by women’s health, cardio, and derma, with new product launches gaining traction. International markets grew 20%, boosted by emerging markets and Europe approvals. Management targets 13-14% revenue growth and 150 bp margin expansion in FY26, focusing on complex injectables, biosimilars, ADCs, and operational efficiencies. Debt is likely to be fully repaid by FY26-end.